Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Orphan drug designation means that the sponsor qualifies for certain benefits, such as reduced taxes, from the federal government to help in development of pharmaceuticals to specifically treat rare medical condition of <200,000 people. Since Brilacidin is a developed proven drug it may not or even need to qualify for orphan status to bring it to market. IMO

Leo said in Dec 20 PR:
Brilacidin-OM, a defensin mimetic compound has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo.